NGM Biopharmaceuticals, Inc., a privately-held biopharmaceutical company, named Jeff Jonker president and David Woodhouse, Ph.D., as chief financial officer.

Prior to joining NGM, Mr. Jonker was the senior vice president, corporate and business development at Theravance Biopharma and Theravance, Inc. He previously served as the chief business officer of Satori Pharmaceuticals and the vice president of business development and corporate strategy for Gloucester Pharmaceuticals, prior to its acquisition by Celgene. He also held leadership positions in the business development and legal groups at Genentech.

Dr. Woodhouse joins NGM from Goldman Sachs, where he was managing director and co-head of U.S. biotechnology investment banking. As a member of Goldman’s healthcare investment banking group for nearly 13 years in the New York and San Francisco offices, Dr. Woodhouse’s responsibilities included corporate finance and mergers and acquisitions advice for the biotechnology, specialty pharma and diagnostics industries. In this capacity, he advised on several billion dollars in equity and equity- linked financings, as well as more than $90 billion in M&A transactions. Prior to Goldman, he worked in various business development and research roles at Dynavax Technologies Corporation and Amgen, Inc.